Posted by Michael Wonder on 14 Jan 2023
Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
12 January 2023 - Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adults.
Roche today announced that the European Commission has approved Xofluza (baloxavir marboxil) in children aged one year and above for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza.
